Fireflies are lighting up summer skies. But the glowing bugs are still on the decline
There's no official count, but experts say a particularly wet spring may have created the ideal conditions for young fireflies to grow into adults to set summer nights aglow.
Fireflies light the night everywhere: There are over 2,000 known species across the globe. They use their characteristic flashes to communicate and find the perfect mate.
In New York City, the lightning bugs are out in the five boroughs, sparkling once the sun goes down in places like Central Park and Prospect Park. The summer months are ideal to spot them as they start to dwindle throughout the month of August.
While northeastern nights may seem brighter this summer, the bugs are still on the decline and they're waning at a faster rate than ever before.
'It would be a mistake to say firefly populations are high this year, therefore there's no decline,' said Matt Schlesinger with the New York Natural Heritage Program, who is part of an effort to count fireflies in state parks.
Habitat loss, pesticide use and light pollution are responsible for a decline in population. In cities, blaring lights from billboards, cars and storefronts can drown out the bugs' glow, making it harder for them to find their kin and pass their genes onto the next generation.
Fireflies are part of the story of summer, said entomologist Jessica Ware with the American Museum of Natural History. Her children grew up seeing them flash in her backyard, but the bugs started to disappear once her kids hit their teenage years.
In the past few months, her family has seen the fireflies come back. Their return made her think about all the kids who are glimpsing the glowing bugs for the very first time.
'It shouldn't be new,' Ware said. 'It should be something that is a universal part of summer.'
To look out for fireflies, consider turning the lights off at night and avoid spraying front lawns with insecticides.
'We still need to do some work ourselves, to change our behavior, to really make sure that large populations can continue to stay large,' Ware said.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Will we see the northern lights in Oklahoma tonight? See aurora forecast
When experienced stargazers in the continental United States hear the words, "geomagnetic storm," likely one question comes to mind: Are we getting some northern lights? In this case, the answer is yes, but it may depend on where you live. An explosion on the sun's outermost atmosphere of charged particles, known as a coronal mass ejection, has been hurtling toward Earth since Tuesday, Aug. 5, according to the National Oceanic and Atmospheric Administration. The agency's Space Weather Prediction Center has since been tracking the ejection, which it said has the potential to soon trigger a geomagnetic storm on Earth. What does that mean for skywatchers? Well, the particles flowing from the sun could interact with our planet's magnetosphere in ways that trigger the northern lights, also known as the aurora borealis. For the next two nights, the luminous green and red glow of the auroras may be more widely visible than is typical in up to 18 states in the U.S. Here's everything to know about the solar storm, as well as where and when to see the northern lights it could produce in the U.S. Northern Lights: The sun is spewing massive solar flares toward Earth Could geomagnetic storm disrupt communications on Earth? Weaker solar activity won't be noticeable here on Earth. But a geomagnetic storm with enough energy output has the potential to disrupt satellites, communications systems, and even ground-based technologies like power grids if directed at our planet. In extreme cases, powerful solar events even pose risks to spacecraft and astronauts, NASA says. About a year ago, in May 2024, a historically powerful geomagnetic storm was responsible for some reports of power grid irregularities and interference with GPS signals – even farming equipment. On the bright side, it also unleashed spectacular views of the northern lights in parts of the country where auroras are not often visible. In this case, a rapid, intense flash of electromagnetic energy ranks as a G1-G2 on NOAA's scale, indicating a minor-moderate geomagnetic storm that could cause "manageable effects to some technological infrastructure," the agency stated. A moderate geomagnetic storm is also strong enough to unleash views of the northern lights, also known as auroras, in some northern and upper midwest states. What are the northern lights? The auroras are a natural light display in Earth's sky that are famously best seen in high-latitude regions of the Northern and Southern hemispheres. The phenomenon is caused when electrically charged particles from space enter Earth's atmosphere and collide with molecules and gases like oxygen and nitrogen, causing the atmospheric particles to gain energy. To return to their normal state, the particles release that energy in the form of light, according to the University of Alaska at Fairbanks Geophysical Institute website, which tracks the phenomenon. As auroras form, Earth's magnetic field redirects the particles toward the poles through a process that produces a stunning display of rays, spirals and flickers that have fascinated humans for millennia. Whether hues of green, red, blue and even pink dance about in the sky depends on the altitude where the collisions occur, as well as the composition and density of the atmosphere at the time. Where could auroras be visible? For most of the time, auroras are best seen around the magnetic poles of the Northern and Southern hemispheres in Europe, Asia and North America. In the U.S., Alaska is well known to have the best viewing opportunities for the northern lights. But a geomagnetic storm tracked by the National Oceanic and Atmospheric Administration is expected to make the auroras visible farther from the poles. The geomagnetic activity detected by NOAA's Space Weather Prediction Center has a Kp index of 6 on Thursday, Aug. 7, meaning the northern lights will be active and brighter further from the poles, according to the agency. "At this geomagnetic activity level, it might be possible to see the aurora from the northern edge of the United States," NOAA says on its website. In the U.S., the auroras will be visible Thursday to at least the northern parts of the following states: Washington Idaho Montana North Dakota South Dakota Minnesota Wisconisn Michigan A thin red "viewline" representing the southern-most locations from which you may see the aurora on the northern horizon extends to: Oregon Wyoming Nebraska Iowa Illinois Indiana New York Vermont New Hampshire Maine Will we see the northern lights in Oklahoma? It's possible, though unlikely this time. The best chance of seeing auroras late at night is to look north between 9 p.m. and 6 a.m. local time, and away from city lights. This far south, the lights are best seen with a camera, even the one that comes equipped with your smartphone. Although some maps and forecasts have predicted low visibility in southern states, some Oklahomans have still documented nights throughout the summer when they saw the lights in the late-night hours. Geomagnetic storm could produce auroras again Friday night The geomagentic storm will be less powerful Friday, Aug. 8, but is forecast to still be strong enough to trigger the northern lights once again across the northern U.S. By then, though, NOAA predicts the KP index will be downgraded to a 5, which still means the auroras are still bright further than usual from the poles. "If you are in the right place, these aurora can be quite pleasing to look at," according to NOAA's description of of 5-rating on the KP scale. When, how to see the northern lights Even though conditions are prime for more impending aurora shows, experts have long struggled to accurately forecast exactly when and where the phenomenon will ever occur. Even the best predictions can accurately be made only a few days or even hours in advance. But as a rule of thumb, if the weather is clear, the best aurora is usually visible within an hour or two of midnight, according to NOAA. And if it looks as if the northern lights will flare up near you, you should get away from cities and travel to dark locations free from light pollution so you can best see them. The agency also maintains an aurora dashboard that should help skygazers track the phenomenon. NOAA's 30-minute aurora forecast may be particularly useful for regular updates on viewing opportunities. This article originally appeared on Oklahoman: Northern lights possible across the US. See forecast for Oklahoma Solve the daily Crossword
Fox News
6 hours ago
- Fox News
Could chikungunya virus spread to US? Here's what Americans should know
A mosquito-borne virus has led to a widespread outbreak in China – but could it show up in the U.S.? The U.S. Centers for Disease Control and Prevention (CDC) issued a Level 2 alert on Wednesday for an outbreak of chikungunya virus in the Guangdong Province, where health officials have reported more than 7,000 cases, per the Associated Press (AP). There are efforts underway to control the mosquitoes spreading the virus, including the use of nets, insecticide and drones, the report stated. Chikungunya cases have also been spreading throughout Europe, according to the European Centre for Disease Prevention and Control (ECDC). The virus is transmitted when a mosquito feeds on an infected person and then bites someone else. Dr. Paul Sax, clinical director of the Division of Infectious Diseases at Brigham and Women's Hospital in Boston, said an outbreak in the U.S. is unlikely. Chikungunya is a predominantly tropical virus spread through Aedes mosquitoes, which can be found in the southern United States. "The reason why we don't have lots of chikungunya, dengue or Zika in the United States is that there isn't that many of those mosquitoes here," Sax said. "To really sustain an outbreak of chikungunya in the United States, you need to have a lot more people with chikungunya. And we only occasionally have people with that." "If there isn't very much circulating chikungunya in our community, we're not going to see a sustained epidemic." It is mainly Americans who have recently traveled to highly endemic areas of the world who could potentially contract chikungunya, the expert noted — and then they would have to be bitten by mosquitoes that spread it to others. "So, it's very unlikely to have a big outbreak, but if we were to have an outbreak – it's most likely to occur in places like Florida, Louisiana and Texas," Sax said. There was a recent case of chikungunya at Brigham and Women's hospital involving a patient who had traveled to Bolivia, the doctor shared. "She contracted it there and then came back here and was diagnosed here," he said. "But that person then has to be bitten by an Aedes mosquito, which then transmits it to another person … If there isn't very much circulating chikungunya in our community, we're not going to see a sustained epidemic." Symptoms of the chikungunya virus typically include fever, headache and severe joint pain. The joint pain can last weeks or even months after the initial infection, Sax shared. There is no antiviral treatment for chikungunya, but some patients may see a joint specialist who can prescribe anti-inflammatory drugs. Over-the-counter anti-inflammatories like ibuprofen can also help relieve symptoms, according to Sax. Two vaccines also exist – IXCHIQ and VIMKUNYA – which are a popular choice for those who travel to highly endemic regions. Dr. Neil Maniar, Ph.D., professor of public health practice in the Department of Public Health & Health Sciences at Northeastern University in Boston, agreed that the risk of chikungunya in the U.S. is low. In a separate interview with Fox News Digital, Maniar suggested that the outbreak in China is most likely related to their monsoon season, as pests like mosquitoes and even ticks thrive in warm, wet environments. The expert encouraged people to take proper precautions when traveling or visiting tropical areas, even in the U.S. Those include using bug repellent, wearing long pants and receiving appropriate vaccinations when traveling to affected areas. "We're seeing an increase in illnesses that are transmitted by mosquitoes and ticks because we're seeing longer seasons where they can thrive," he said. "The population of mosquitoes and ticks is just growing … and I think that's something we should all pay attention to."
Yahoo
6 hours ago
- Yahoo
Ginkgo Bioworks Reports Second Quarter 2025 Financial Results
Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets BOSTON, Aug. 7, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2025. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information will be available at Second Quarter 2025 Financial Results Second quarter 2025 Total revenue of $50 million, down from $56 million in the comparable prior year period Second quarter 2025 Cell Engineering revenue of $39 million, up from $36 million in the comparable prior year period, an increase of 8%, primarily driven by growth with biopharma and government customers Second quarter 2025 Biosecurity revenue of $10 million, down from $20 million in the comparable prior year period Second quarter 2025 GAAP net loss of $(60) million, compared to $(217) million in the comparable prior year period Second quarter 2025 Adjusted EBITDA of $(28) million, up from $(99) million in the comparable prior year period, driven by a decrease in operating expenses Cash, cash equivalents and marketable securities balance as of June 30, 2025 of $474 million "Our platform is proving to be a critical engine for AI in biology, with growing demand for our automation and data generation capabilities," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "This is translating into commercial traction, including major new government contracts and expanded service offerings in response to demand in the biopharma industry. This progress is backed by rigorous financial discipline, allowing us to achieve our $250 million annualized cost-reduction goal three months ahead of schedule." Recent Business Highlights & Strategic Positioning Ginkgo's Automation and Datapoints offerings continue to establish themselves as critical tools in AI-powered bioengineering Pacific Northwest National Laboratory (PNNL) selected Ginkgo Automation to deliver a state-of-the-art automated anaerobic phenotyping platform, to assist with what is believed to be the largest automated anaerobic system for research in the world Ginkgo launched a new in vitro ADME profiling Service, built on its proprietary RAC automation system. Designed for scale and efficiency, the Service delivers assay quality at cost-effective pricing and includes a price-matching guarantee. By automating traditionally labor-intensive assays and executing them onshore, Ginkgo enables customers to profile more compounds earlier, accelerate decision-making, train AI/ML models, and reduce costs while protecting valuable IP. This launch strengthens Ginkgo's position as a differentiated US-based partner in preclinical R&D analytical services for small molecule drug development. Ginkgo launched its first direct-to-scientist product: a cell-free protein synthesis system This E. coli-based system is optimized for high production from linear DNA, increased solubility of difficult-to-express proteins, and compatibility with automation Ginkgo continues to progress towards its objective to reach Adjusted EBITDA breakeven by the end of 2026 Ginkgo has achieved its target to reach $250 million in annualized cost reduction three months ahead of schedule, through reductions in force and other cost cutting measures. Site consolidation efforts were substantially completed by the year ended 2024, with excess space available for sublease. Full Year 2025 Outlook Ginkgo reaffirms Total revenue of $167-$187 million in 2025 Ginkgo continues to expect Cell Engineering revenue of $117-$137 million in 2025 Ginkgo expects Biosecurity revenue of at least $40 million in 2025 Conference Call DetailsGinkgo will host a videoconference today, Thursday, August 7, 2025, beginning at 5:30 p.m. ET. The presentation will include an overview of the second quarter of 2025, recent business updates, a discussion on Ginkgo's outlook, as well as a moderated question and answer session. To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation. Ginkgo Investor Website: Audio-Only Dial Ins: +1 646 876 9923 (New York)+1 301 715 8592 (Washington DC)+1 305 224 1968 (Miami)+1 312 626 6799 (Chicago)+1 346 248 7799 (Houston)+1 408 638 0968 (San Jose)+1 564 217 2000 (Seattle)+1 689 278 1000 (Orlando)Webinar ID: 953 3421 4604 If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our website at for updated dial-in information. About Ginkgo BioworksGinkgo Bioworks builds the tools that make biology easier to engineer for everyone. Ginkgo R&D Solutions delivers customizable R&D packages—such as protein engineering, nucleic acid design, and cell-free systems—giving partners a comprehensive way to accelerate innovation across therapeutics, diagnostics, & manufacturing. Ginkgo Automation sells modular, integrated laboratory automation so scientists can spend their days planning and analyzing experiments rather than pipetting in the lab. Ginkgo Datapoints uses Ginkgo's in-house automation to generate the large lab data sets to power your AI models. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit and read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn. Forward-Looking Statements of Ginkgo BioworksThis press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers' needs, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, including the timing for attaining Adjusted EBITDA breakeven, impacts of our restructuring, potential customer success, including successful application of our offerings by our customers, and expectations with regard to revenue, including our ability to meet all milestones and achieve the maximum revenue available under certain of our customer arrangements, expenses, our full year 2025 outlook, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 25, 2025 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations. Use of Non-GAAP Financial MeasuresCertain of the financial measures included in this release, including Adjusted EBITDA, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures. Ginkgo Bioworks Contacts: INVESTOR CONTACT:investors@ MEDIA CONTACT:press@ Ginkgo Bioworks Holdings, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share data) As of June 30, 2025As of December 31, 2024 AssetsCurrent assets:Cash and cash equivalents $ 203,566$ 561,572 Marketable securities 270,125— Accounts receivable, net 22,15221,857 Accounts receivable - related parties 974586 Prepaid expenses and other current assets 26,20818,729 Total current assets 523,025602,744 Property, plant and equipment, net 186,354203,720 Operating lease right-of-use assets 375,796394,435 Investments 32,66248,704 Intangible assets, net 66,15272,510 Other non-current assets 47,02055,336 Total assets $ 1,231,009$ 1,377,449 Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable $ 11,202$ 14,169 Deferred revenue (includes $311 and $795 from related parties) 28,28727,710 Accrued expenses and other current liabilities 57,23165,387 Total current liabilities 96,720107,266 Non-current liabilities:Deferred revenue, net of current portion (includes $64,786 and $72,260 from related parties) 74,56698,783 Operating lease liabilities, non-current 428,827438,766 Other non-current liabilities 17,94416,576 Total liabilities 618,057661,391 Commitments and contingencies (Note 10)Stockholders' equity:Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued —— Common stock, $0.0001 par value (Note 8) 65 Additional paid-in capital 6,600,1076,555,416 Accumulated deficit (5,988,814)(5,837,557) Accumulated other comprehensive income (loss) 1,653(1,806) Total stockholders' equity 612,952716,058 Total liabilities and stockholders' equity $ 1,231,009$ 1,377,449 The accompanying notes are an integral part of these condensed consolidated financial statements. Ginkgo Bioworks Holdings, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (in thousands, except share data) Three Months Ended June 30,Six Months Ended June 30,2025202420252024 Cell Engineering revenue (1) $ 39,134$ 36,205$ 77,364$ 64,094 Biosecurity revenue 10,47020,00120,55830,056 Total revenue 49,60456,20697,92294,150 Costs and operating expenses:Cost of Biosecurity revenue 9,44211,80717,39921,009 Cost of other revenue 5,3801,9149,4701,914 Research and development 53,370134,221124,293270,678 General and administrative 43,27966,28592,322136,572 Goodwill impairment —47,858—47,858 Restructuring charges 3,67417,0668,94717,066 Total operating expenses 115,145279,151252,431495,097 Loss from operations (65,541)(222,945)(154,509)(400,947) Other income (expense):Interest income, net 6,08310,31312,16422,024 Loss on investments (229)(6,826)(3,922)(9,370) Change in fair value of warrant liabilities —3,233—4,173 Other income (expense), net (896)(766)(5,185)1,249 Total other income 4,9585,9543,05718,076 Loss before income taxes (60,583)(216,991)(151,452)(382,871) Income tax (benefit) expense (283)190(195)221 Net loss $ (60,300)$ (217,181)$ (151,257)$ (383,092) Net loss per share:Basic $ (1.10)$ (4.23)$ (2.77)$ (7.55) Diluted $ (1.10)$ (4.23)$ (2.77)$ (7.56) Weighted average common shares outstanding:Basic 54,858,98251,370,02954,552,00650,740,744 Diluted 54,858,98251,375,59954,552,00650,746,314 Comprehensive loss:Net loss $ (60,300)$ (217,181)$ (151,257)$ (383,092) Other comprehensive (loss) income:Foreign currency translation adjustment 2,586(172)3,435(3,207) Unrealized gains (loss) on available-for-sale securities (83)—24— Total other comprehensive (loss) income 2,503(172)3,459(3,207) Comprehensive loss $ (57,797)$ (217,353)$ (147,798)$ (386,299) (1) Includes related party revenue of $420 and $5,146 for the three months ended June 30, 2025 and 2024, respectively, and $8,518 and $5,819 for the six months ended June 30, 2025 and 2024, respectively. Ginkgo Bioworks Holdings, Inc. Condensed Consolidated Statements of Cash Flows (unaudited) (in thousands) Six Months Ended June 30,20252024 Cash flows from operating activities:Net loss $ (151,257)$ (383,092) Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization 31,15930,199 Stock-based compensation 42,67877,928 Goodwill impairment —47,858 Restructuring related impairment charges —4,823 Loss on investments 3,9589,370 Change in fair value of notes receivable 5,2851 Change in fair value of warrant liabilities —(4,173) Change in fair value of contingent consideration (4,232)2,284 Non-cash lease expense 14,86613,070 Non-cash in-process research and development —19,795 Other non-cash activity 462,096 Changes in operating assets and liabilities:Accounts receivable (412)(1,102) Prepaid expenses and other current assets (2,272)1,770 Operating lease right-of-use assets 3,81414,373 Other non-current assets (125)(833) Accounts payable, accrued expenses and other current liabilities (5,125)10,864 Deferred revenue, current and non-current ($7,958) and ($4,577) from related parties (23,676)(17,012) Operating lease liabilities, current and non-current (11,638)(3,866) Other non-current liabilities 5,1561,998 Net cash used in operating activities (91,775)(173,649) Cash flows from investing activities:Purchases of marketable debt securities (320,132)— Maturities of marketable debt securities 64,958— Purchases of property and equipment (7,660)(33,742) Business acquisition —(5,400) Other 262191 Net cash used in investing activities (262,572)(38,951) Cash flows from financing activities:Proceeds from exercise of stock options —84 Principal payments on finance leases (305)(494) Contingent consideration payment —(661) Net cash used in financing activities (305)(1,071) Effect of foreign exchange rates on cash and cash equivalents 260(173) Net decrease in cash, cash equivalents and restricted cash (354,392)(213,844) Cash and cash equivalents, beginning of period 561,572944,073 Restricted cash, beginning of period 44,17145,511 Cash, cash equivalents and restricted cash, beginning of period 605,743989,584 Cash and cash equivalents, end of period 203,566730,367 Restricted cash, end of period 47,78545,373 Cash, cash equivalents and restricted cash, end of period $ 251,351$ 775,740 Ginkgo Bioworks Holdings, Inc. Segment Information (in thousands, unaudited) Three Months Ended June 30,Six Months Ended June 30,2025 202420252024 Cell Engineering Revenue $ 39,134 $ 36,205$ 77,364$ 64,094 Costs and operating expenses: Cost of other revenue 3,865 1,9146,9861,914 Research and development 31,065 84,11379,735166,011 General and administrative 14,141 33,20232,16871,446 Cell Engineering operating loss (9,937) (83,024)(41,525)(175,277) Biosecurity Revenue 10,470 20,00120,55830,056 Costs and operating expenses: Cost of Biosecurity revenue 8,583 11,80715,80621,009 Research and development — 458—578 General and administrative 6,702 11,17914,75123,130 Biosecurity operating loss (4,815) (3,443)(9,999)(14,661) Total segment operating loss (14,752) (86,467)(51,524)(189,938) Reconciling items to reconcile total segment operating loss to loss before income taxes: Stock-based compensation (1) 22,526 38,22643,32680,623 Goodwill impairment — 47,858—47,858 Depreciation and amortization 15,793 17,33031,15930,199 Restructuring charges (2) 3,674 17,0668,94717,066 Carrying cost of excess space (net of sublease income) (3) 12,413 7,38324,0887,383 Merger and acquisition related expense (income) (4) (3,617) 4,512(4,535)6,906 Acquired in-process research and development — 2,978—19,849 Other (income) expense, net (5) (4,958) (4,829)(3,057)(16,951) Loss before income taxes $ (60,583) $ (216,991)$ (151,452)$ (382,871) (1) Includes $0.3 million and $1.1 million in employer payroll taxes for the three months ended June 30, 2025 and 2024, respectively, and $0.6 million and $2.7 million in employer payroll taxes for six months ended June 30, 2025 and 2024, respectively. (2) See Note 3, Restructuring, for composition of costs. (3) The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces. (4) Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs. (5) Includes interest income, interest expense, loss on investments, changes in fair value of certain assets and liabilities, and other gains and losses. Ginkgo Bioworks Holdings, Inc. Selected Non-GAAP Financial Measures (in thousands, unaudited) Three Months Ended June 30,Six Months Ended June 30, (in thousands) 2025202420252024 Net loss (1) $ (60,300)$ (217,181)$ (151,257)$ (383,092) Interest income, net (6,083)(10,313)(12,164)(22,024) Income tax (benefit) expense (283)190(195)221 Depreciation and amortization 15,79317,33031,15930,199 EBITDA (50,873)(209,974)(132,457)(374,696) Stock-based compensation (2) 22,52638,22643,32680,623 Goodwill impairment —47,858—47,858 Restructuring charges (3) 3,67417,0668,94717,066 Merger and acquisition related expense (income) (4) (3,617)4,512(4,535)6,906 Loss on investments 2296,8263,9229,370 Change in fair value of warrant liabilities —(3,233)—(4,173) Change in fair value of convertible notes —(480)5,285846 Adjusted EBITDA $ (28,061)$ (99,199)$ (75,512)$ (216,200) (1) All periods include non-cash revenue when earned, including $7.5 million recognized in the six months ended June 30, 2025, pursuant to the release of deferred revenue related to the mutual termination of a customer agreement. (2) Includes $0.3 million and $1.1 million in employer payroll taxes for the three months ended June 30, 2025 and 2024, respectively, and $0.6 million and $2.7 million for the six months ended June 30, 2025 and 2024, respectively. (3) Restructuring charges primarily consist of employee termination costs from the reduction in force commenced in June 2024. (4) Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs. Not included in this adjustment are acquired in-process research and development expenses, which totaled zero and $3.0 million for the three months ended June 30, 2025 and 2024, respectively, and zero and $19.8 million for the six months ended June 30, 2025 and 2024, respectively. View original content to download multimedia: SOURCE Ginkgo Bioworks Error in retrieving data Sign in to access your portfolio Error in retrieving data
